PITTSBURGH, July 11 /PRNewswire/ -- iNTELOMED, Inc. and the Pittsburgh Life Sciences Greenhouse (PLSG), the private/public partnership putting the region’s life sciences industry on a fast track for growth, announced that the PLSG has committed a $100,000 investment to iNTELOMED.
The investment will be used to help iNTELOMED with clinical proof-of-concept testing and initial prototype development of CVInsight(TM), a non-invasive medical device that overcomes the limitations of the current protocol of using static vital signs as a basis for assessing cardiovascular sufficiency. By performing a rapid and safe bedside test, the CVInsight(TM) device provides a functional measure of a patient’s cardiovascular stability, or lack thereof. The assessment of cardiovascular stability is performed using a stress test created from a passive leg raise; a proven way to create a safe cardiovascular “stress” measurement.
The first application of the CVInsight(TM) device will focus on heart failure patients in critical care centers such as hospital Intensive Care Units (ICUs). Statistics show that heart failure patients are frequently admitted to the ICU more than is necessary. In addition, the patient management solutions that currently determine when it is appropriate to discharge cardiovascular patients offer little insight as to whether the cardiovascular system is meeting its primary objective of circulating adequate oxygen to meet metabolic needs; the basis of a healthy, functioning body.
“The iNTELOMED technology has the potential to provide clinicians with a straightforward, more objective assessment when trying to evaluate who is an at-risk patient versus a low-risk patient in the ICU,” said John W. Manzetti, PLSG’s President & Chief Executive Officer. “The investment by the PLSG will help iNTELOMED develop and test the accuracy of the CVInsight(TM) device.” Manzetti continues, “This will improve patient care and ultimately help diminish the occurrence of acute events and mortality of cardiovascular patients worldwide.”
“We are eager to begin a pilot study that will be performed to conduct clinical testing in an ICU setting,” said Jan Berkow, Chief Executive Officer of iNTELOMED. “We are delighted to have the PLSG as an investor; without their support we would not be able to conduct the pilot study and develop our CVInsight(TM) prototype.”
About the Pittsburgh Life Sciences Greenhouse (PLSG) invests in and supports the growth of biosciences companies in Southwestern Pennsylvania. The PLSG has investment and business growth programs to increase the linkage between research, technology and commercialization; nurture and develop entrepreneurial biosciences enterprises; grow the region’s talent pool in the life sciences; and help biosciences firms locate, expand or start-up in the Greater Pittsburgh region. http://www.plsg.com
About iNTELOMED
iNTELOMED is a technology company with competencies that center on novel functional cardiovascular assessment methods led by CEO, Jan Berkow and fellow co-founders Dr. Michael Pinsky, a world-renowned cardiovascular physiologist and critical care clinician and Dr. Juan Carlos Puyana, a thought leader in cellular resuscitation research and respected trauma surgeon are currently on staff at the University of Pittsburgh Medical Center (UPMC).
Pittsburgh Life Sciences Greenhouse
CONTACT: Lynn Banaszak Brusco of Pittsburgh Life Sciences Greenhouse,+1-412-770-1353
Web site: http://www.plsg.com/
